Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases

被引：0
|
作者：
Crino, L. [1 ]
Horn, L. [2 ]
Felip, E. [3 ]
Frontera, O. Aren [4 ]
Burgio, M. [1 ]
Waterhouse, D. [5 ]
Blumenschein, G. [6 ]
Barlesi, F. [7 ]
Garassino, M. [8 ]
Holgado, E. [9 ]
Antonia, S. [10 ]
Spigel, D. [11 ]
Gainor, J. [12 ]
Gettinger, S. [13 ]
Geese, W. [14 ]
Li, A. [14 ]
Healey, D. [14 ]
Ready, N. [15 ]
机构：
[1] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori Irst, Meldola, Italy
[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[3] Hosp Univ Vall dHebron, Barcelona, Spain
[4] Ctr Int Estudios Clin, Santiago, Chile
[5] Oncol Hematol Care Ohc Us Oncol, Cincinnati, OH USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Aix Marseille Univ, AP HM, Marseille, France
[8] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[9] Hosp Madrid, Madrid, Spain
[10] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[11] Tennessee Oncol Pllc, Sarah Cannon Res Inst, Nashville, TN USA
[12] Massachusetts Gen Hosp, Boston, MA 02114 USA
[13] Yale Comprehens Canc Ctr, New Haven, CT USA
[14] Bristol Myers Squibb, Princeton, NJ USA
[15] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Nivolumab; non-small cell lung cancer;
D O I：
10.1016/j.jtho.2017.09.1703
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.07-012
引用
收藏
页码：S2302 / S2302
页数：1
相关论文
共 50 条
  • [1] Feasibility Study of Nivolumab and Docetaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Shimokawa, T.
    Nakamura, Y.
    Iwasawa, S.
    Miyazaki, K.
    Yamanaka, T.
    Takiguchi, Y.
    Okamoto, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2431 - S2431
  • [2] Feasibility study of nivolumab and docetaxel in previously treated patients with advanced non-small cell lung cancer
    Miyazaki, Kazuhito
    Iwasawa, Shunichiro
    Nakamura, Yukiko
    Shimokawa, Tsuneo
    Yamanaka, Takeharu
    Takiguchi, Yuichi
    Okamoto, Hiroaki
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Qiao Liu
    Xia Luo
    Liubao Peng
    Lidan Yi
    Xiaomin Wan
    Xiaohui Zeng
    Chongqing Tan
    Clinical Drug Investigation, 2020, 40 : 129 - 137
  • [4] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Liu, Qiao
    Luo, Xia
    Peng, Liubao
    Yi, Lidan
    Wan, Xiaomin
    Zeng, Xiaohui
    Tan, Chongqing
    CLINICAL DRUG INVESTIGATION, 2020, 40 (02) : 129 - 137
  • [5] Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer
    Ramagopalan, Sreeram
    Gupta, Alind
    Arora, Paul
    Thorlund, Kristian
    Ray, Joshua
    Subbiah, Vivek
    JAMA NETWORK OPEN, 2021, 4 (11)
  • [6] Monotherapy with docetaxel in previously treated patients with advanced non-small cell lung carcinoma
    Courousis, C
    Androulakis, N
    Heras, P
    Vamvakas, I
    Metaxaris, G
    Souklakos, J
    Vlastos, F
    Dimadi, M
    Vossos, A
    Aravosita, P
    Georgopoulou, T
    Papandreou, A
    Hatzidaki, D
    Papadakis, E
    Georgoulias, V
    2ND INTERNATIONAL CONGRESS ON LUNG CANCER, 1996, : 571 - 574
  • [7] Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
    Vokes, E. E.
    Ready, N.
    Felip, E.
    Horn, L.
    Burgio, M. A.
    Antonia, S. J.
    Frontera, O. Aren
    Gettinger, S.
    Holgado, E.
    Spigel, D.
    Waterhouse, D.
    Domine, M.
    Garassinoio, M.
    Chow, L. Q. M.
    Blumenschein, G., Jr.
    Barlesi, F.
    Coudert, B.
    Gainor, J.
    Arrieta, O.
    Brahmer, J.
    Butts, C.
    Steins, M.
    Geese, W. J.
    Li, A.
    Healey, D.
    Crino, L.
    ANNALS OF ONCOLOGY, 2018, 29 (04) : 959 - 965
  • [8] SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
    Borghaei, H.
    Johnson, M. L.
    Garon, E. B.
    He, K.
    Planchard, D.
    Reck, M.
    Popat, S.
    Herbst, R. S.
    Leal, T. A.
    Dumoulin, D.
    De Marinis, F.
    Reynolds, C. H.
    Theelen, W. S. M. E.
    Percent, I.
    Calderon, V. Gutierrez
    Flandin, A. C. Madroszyk
    Shazer, R. L.
    Yan, X.
    Harrigan, R.
    Peters, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1308 - S1308
  • [9] A randomized phase II/ III trial of nivolumab versus nivolumab plus docetaxel for previously treated advanced or recurrent non-small cell lung cancer: TORG1630.
    Kawashima, Yosuke
    Taniguchi, Yuri
    Shimokawa, Tsuneo
    Takiguchi, Yuichi
    Misumi, Toshihiro
    Nakamura, Atsushi
    Furuya, Naoki
    Tanaka, Kentaro
    Harada, Toshiyuki
    Tanaka, Hisashi
    Miura, Satoru
    Sata, Masafumi
    Kato, Terufumi
    Tokito, Takaaki
    Naoki, Katsuhiko
    Bessho, Akihiro
    Goto, Yasuhiro
    Nakamichi, Shinji
    Okamoto, Hiroaki
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] A Randomized Comparison of Nivolumab versus Nivolumab plus Docetaxel for Previously Treated Advanced or Recurrent ICI-Naive Non-Small Cell Lung Cancer: TORG1630
    Taniguchi, Yuri
    Shimokawa, Tsuneo
    Takiguchi, Yuichi
    Misumi, Toshihiro
    Nakamura, Yukiko
    Kawashima, Yosuke
    Furuya, Naoki
    Shiraishi, Yoshimasa
    Harada, Toshiyuki
    Tanaka, Hisashi
    Miura, Satoru
    Uchiyama, Ayumi
    Nakahara, Yoshiro
    Tokito, Takaaki
    Naoki, Katsuhiko
    Bessho, Akihiro
    Goto, Yasuhiro
    Seike, Masahiro
    Okamoto, Hiroaki
    CLINICAL CANCER RESEARCH, 2022, 28 (20) : 4402 - 4409
12345